para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors

ChemMedChem. 2013 Dec;8(12):1978-85. doi: 10.1002/cmdc.201300337. Epub 2013 Oct 15.

Abstract

Human tankyrases are attractive drug targets, especially for the treatment of cancer. We identified a set of highly potent tankyrase inhibitors based on a 2-phenyl-3,4-dihydroquinazolin-4-one scaffold. Substitutions at the para position of the scaffold's phenyl group were evaluated as a strategy to increase potency and improve selectivity. The best compounds displayed single-digit nanomolar potencies, and profiling against several human diphtheria-toxin-like ADP-ribosyltransferases revealed that a subset of these compounds are highly selective tankyrase inhibitors. The compounds also effectively inhibit Wnt signaling in HEK293 cells. The binding mode of all inhibitors was studied by protein X-ray crystallography. This allowed us to establish a structural basis for the development of highly potent and selective tankyrase inhibitors based on the 2-phenyl-3,4-dihydroquinazolin-4-one scaffold and outline a rational approach to the modification of other inhibitor scaffolds that bind to the nicotinamide site of the catalytic domain.

Keywords: Wnt signaling; inhibitors; structural biology; structure-activity relationships; tankyrase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Catalytic Domain
  • Cell Line
  • Crystallography, X-Ray
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / metabolism
  • Enzyme Inhibitors / toxicity
  • HEK293 Cells
  • Humans
  • Hydrogen Bonding
  • Protein Binding
  • Quinazolinones / chemistry*
  • Quinazolinones / metabolism
  • Quinazolinones / toxicity
  • Static Electricity
  • Structure-Activity Relationship
  • Tankyrases / antagonists & inhibitors*
  • Tankyrases / metabolism
  • Wnt Signaling Pathway / drug effects

Substances

  • Enzyme Inhibitors
  • Quinazolinones
  • Tankyrases
  • TNKS protein, human